转移性去势抵抗性前列腺癌化疗与激素治疗策略  

Strategies to chemotherapy and hormone therapy in the treatment of metastatic castrate-resistantprostate cancer

作　　者：孙卫兵[1] 

机构地区：[1]大连医科大学附属第二医院泌尿外科,辽宁大连116027

出　　处：《大连医科大学学报》2014年第6期511-517,共7页Journal of Dalian Medical University

摘　　要：以多西他赛为核心的化疗方案已经成为转移性去势抵抗性前列腺癌(metastatic castrate-resistant prostate cancer,mCRPC)治疗的一线方案。但在过去的几年中,一些新药的出现改善了患者的总体生存,同时也使优化个体化治疗方案成为可能。已有证据表明阿比特龙、卡巴他赛、镭-223、sipuleucel-T、恩杂鲁胺等与多西他赛一同使去势抵抗性前列腺癌患者生存获益。另外,mCRPC患者对多西他赛一线治疗初始反应良好,出现疾病进展后复治应作为一线治疗的延伸。这些新的治疗手段使mCRPC治疗方案更加复杂化,并且使以往的序贯治疗方案向基于一定规则的新的治疗方式转变。Chemotherapy with docetaxel has become the first line treatment for metastatic castrate-resistantprostate canc-er （ mCRPC） , in the last few years, new agents have been developed to improve survival obviously in this setting and reach a possible optimal personalized treatment strategy.There is evidence to suggest that abiratone acetate, cabazitaxel, radium-223, sipuleucel-T and enzalutamide, together with docetaxel, have demonstrated a survival benefit in these pa-tients.The use of rechallenge with docetaxel in mCRPC patients with disease progression after a first response in the first line treatment should been considered as the extension.These new agents make the scenario more complicated and the chal-lenge to move from the old sequential to a new algorithm-based approach.

关 键 词：去势抵抗性前列腺癌 阿比特龙 镭-223 SIPULEUCEL-T 恩杂鲁胺 多西他赛复治 

分 类 号：R737.25[医药卫生—肿瘤]